DeutschNewstral
Article
Bbarrons.com on 2019-12-13 15:17
Sarepta Stock Is Spiking as FDA Reverses Course, Approving Drug
Related news
- BSarepta Got a Scathing FDA Rejection and Its Stock Is Fallingbarrons.com
- BSarepta Slammed by FDA, Stock Is Now Intriguingbarrons.com
- BSarepta Therapeutics Stock Sinks as FDA Questions Newest Muscular Dystrophy Drugbarrons.com
- BSarepta Could Triple on Expedited FDA Approvalbarrons.com
- FSarepta shares surge 90% on FDA approvalft.com
Sarepta Tumbles With Latest Comments from FDAForbes- Forbes Health Stories: Coffee Won't Lengthen Your Life, And The FDA Reverses CourseForbes
Drugmaker reverses course, plans to seek FDA approval for Alzheimer’s treatmentkfor.com- BSlim Sarepta Hopes Rest With Top FDA Officialbarrons.com
- BSarepta Jumps on FDA Delay but Remains a Buybarrons.com
- MSarepta stock drops after Muscular Dystrophy study halted by FDAmarketwatch.com
- MSarepta Therapeutics shares dive on safety issues in FDA databasemarketwatch.com
- MSarepta stock falls on FDA concerns about drugmarketwatch.com
- MSarepta Therapeutics stock tanks after drug's FDA committee reviewmarketwatch.com
- BSarepta Still a Buy After Expedited FDA Approvalbarrons.com
- BFDA Narrows Its Label on Biogen's Alzheimer's Drug a Month After Approving It3 min readbarrons.com
FDA panelist confirms conflict of interest following Sarepta drug discussionsbizjournals.com- Reporter sues FDA for documents related to Sarepta drug approvalbizjournals.com
- BSarepta Rally Has Legs as FDA Critic Leaves Agencybarrons.com